AIM To evaluate the safety and efficacy of dronedarone in the blanking period in patients underwent atrial fibrillation catheter ablation in the real-world.METHODS A total of 150 patients with atrial fibrillation who underwent catheter ablation at co-operative centers between May 1st,2021 and December 31st,2021 were included.During the blanking period,the patients were given oral dronedarone(400 mg,morning and evening)for 3 months.At 3 months±14 days after surgery,the patients were followed up,and 24-hour Holter,transthoracic echocardiography,liver function and renal function were reviewed.The adverse events occurred during the follow-up were recorded.RESULTS Compared with before surgery,there were no significant differences in heart rate,PR interval,and left ventricular ejection fraction were observed at 3 months after surgery,while QTc interval increased((434.0±29.2)ms vs.(443.5±31.8)ms,P=0.017)).Left atrial diameter((40.6±6.5)mm vs.(38.4±6.0)mm,P=0.007))and lower left ventricular end-diastolic diameter((47.9±4.3)mm vs.(46.4±5.1)mm,P=0.012))decreased.Six patients discontinued in the blanking period(included high atrioventricular block in 1 patient,significant bradycardia in 2 patients,significant prolongation of the QTc interval in 1 patient,and digestive system symptoms in 2 patients).There were no composite endpoints of cardiovascular death,heart failure or rehospitalization associated with antiarrhythmic drugs.At follow-up of 3 months,the rate of sinus rhythm maintenance was 85.3％(128/150).CONCLUSION Dronedarone is safe and effective in the blanking period for patients underwent atrial fibrillation catheter ablation.Moreover,it's good in adherence.
dronedaroneatrial fibrillationradiofrequency ablationanti-arrhythmia agentsblanking period
NETL
NSTL
万方数据
